MIGRANAL® (dihydroergotamine mesylate) is delivered
through a nasal spray – as opposed to orally ingested
medications. This gives you several advantages:
Fast–acting – The active ingredient
is absorbed directly into your bloodstream,
which is why almost 1/3 of MIGRANAL
users get results within a half hour
Works well with nausea – If you
are nauseous or vomiting, taking oral medications can be
hard to do. More importantly,
you may not be able to keep them down. Nasal sprays are
easy to use – no matter how severe your nausea may
be.
Convenient – A nasal sprayer is small and convenient
enough to keep in your pocket (or pocketbook) – for
instant access!
Migranal 8-dose package supplies more of what you need
Migranal 8-dose package provides a 30-day supply of medication to help ensure that you have the medicine you need...when you need to take it.
Now each package of migranal contains 8 easy-to-use sprayers - a convenient 30 day supply with 1 copay.
Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of dihydroergotamine with potent CYP3A4 inhibitors including protease inhibitors and macrolide antibiotics. Because CYP3A4 inhibition elevates the serum levels of dihydroergotamine, the risk for vasospasm leading to cerebral ischemia and/or ischemia of the extremities is increased. Hence, concomitant use of these medications is contraindicated.
Migranal Nasal Spray should not be given to patients with ischemic heart disease (angina pectoris, history of myocardial infarction, or documented silent ischemia) or to patients who have clinical symptoms or findings consistent with coronary artery vasospasm, including Prinzmetal's variant angina. Migranal also should not be given to patients with uncontrolled hypertension, patients who have used 5-HT1 agonists, ergotamine-containing or ergot-type medications or methysergide within the last 24 hours, or patients with hemiplegic or basilar migraine. Migranal Nasal Spray is also contraindicated in patients with known peripheral arterial disease, sepsis, following vascular surgery, and severely impaired hepatic or renal function. Migranal Nasal Spray should not be administered to pregnant women or nursing mothers.
Serious cardiac events, including some that have been fatal, have occurred following use of DHE 45 but are extremely rare. During clinical studies and the foreign postmarketing experience with Migranal Nasal Spray, there have been no fatalities due to cardiac events.
The most commonly reported adverse events in clinical trials for Migranal Nasal Spray were rhinitis, altered sense of taste, application site reactions, dizziness, nausea and vomiting. Adverse events associated with discontinuation were rhinitis, dizziness, facial edema, cold sweats, accidental trauma, depression, elective surgery, somnolence, allergy, vomiting, hypotension, and paresthesia.
MIGRANAL® (dihydroergotamine mesylate) is delivered
through a nasal spray – as opposed to orally ingested
medications. This gives you several advantages: 
